Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders.

It is classified as a potassium-competitive acid blocker.

[1][2] In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD).

[3] In addition, it is in Phase III clinical trials for gastric ulcer and peptic ulcer.

This drug article relating to the gastrointestinal system is a stub.